Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
GlaxoSmithKline
OSI Pharmaceuticals
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT01027598
First received: December 4, 2009
Last updated: April 1, 2014
Last verified: April 2014
  Purpose

This randomized, placebo-controlled, Phase II trial will compare the combination of erlotinib with pazopanib (providing concurrent EGFR and VEGFR inhibition) with erlotinib alone in the second- or third-line treatment of patients with advanced NSCLC. This study will be conducted though the Sarah Cannon Research Consortium, a community-based clinical trial network.


Condition Intervention Phase
Non Small Cell Lung Cancer
Drug: Pazopanib
Drug: Erlotinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by SCRI Development Innovations, LLC:

Primary Outcome Measures:
  • To assess the progression-free survival of patients with advanced non-small-cell lung cancer receiving either erlotinib and pazopanib or erlotinib and placebo. [ Time Frame: 14 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess: ORR,OS,overall toxicity,duration of response, TTP, TTF, safety, correlation of EGFR, EGFR WT (wild-type)/mutation status, cMET, and K-ras WT/mutation status in archival tumor with clinical outcome variables [ Time Frame: 14 months ] [ Designated as safety issue: No ]

Enrollment: 201
Study Start Date: January 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Erlotinib + Pazopanib Erlotinib: 150 mg orally daily Pazopanib: 600 mg orally daily
Drug: Pazopanib
Pazopanib: 600 mg orally daily
Other Name: Votrient
Drug: Erlotinib
Erlotinib: 150 mg orally daily
Other Name: Tarceva
Placebo Comparator: Arm B
Erlotinib + Placebo Erlotinib: 150 mg orally daily Placebo: orally daily
Drug: Erlotinib
Erlotinib: 150 mg orally daily
Other Name: Tarceva

Detailed Description:

Erlotinib is the current treatment standard for second- or third-line therapy of advanced NSCLC. Since angiogenesis inhibitors have also shown activity in NSCLC, the simultaneous inhibition of the EGFR and VEGF pathway may improve the efficacy of therapy. In a recently reported Phase III trial (Hainsworth et al. 2008), the combination of bevacizumab and erlotinib improved the Progression- Free-Survival (PFS) vs. erlotinib alone when given as second-line therapy in NSCLC (3.4 months vs. 1.7 months, respectively; HR 0.63). Pazopanib also inhibits the angiogenesis pathway, and may have advantages over bevacizumab including: (1) inhibition of other potentially important targets, including PDGFR; and (2) more convenient oral administration.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Pathologic confirmation of stage IIIB/IV or relapsed NSCLC (squamous carcinoma, adenocarcinoma, or large cell carcinoma). Patients with mixed tumors with small- cell elements are ineligible.
  2. At least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques, or as >10 mm with spiral computerized tomography (CT) scan according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Eisenhauer et al. 2009)
  3. Failure of at least 1, and no more than 2, prior chemotherapy regimens for advanced disease (either due to progressive disease or toxicity).
  4. Recovery from any toxic effects of prior therapy to ≤grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events.
  5. Completion of radiation therapy at least 28 days prior to the start of study treatment (not including palliative local radiation). Previously irradiated lesions in the advanced setting cannot be included as target lesions unless clear tumor progression has been observed since the end of radiation.
  6. An Eastern Cooperative Oncology Group Performance Status of 0-2.
  7. Adequate organ system function as defined within the protocol.
  8. A female is eligible to enter and participate in this study if she is of non-childbearing potential or of childbearing potential.
  9. Patients entering this study must be willing to provide tissue from previous tumor biopsy (if available) for correlative tissue testing.
  10. Patients ≤18 years of age.
  11. Patients must be able to understand the nature of this study, give written informed consent, and comply with study requirements.

Exclusion Criteria

  1. Past or current history of neoplasm (other than the entry diagnosis), with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone, and a disease-free survival ≤3 years.
  2. Prior treatment with EGFR tyrosine kinase inhibitors (EGFR TKIs) or vascular endothelial factor receptor tyrosine kinase inhibitors (VEGFR TKIs) for NSCLC. [Note: prior bevacizumab (Avastin®) use is permitted].
  3. Prior use of an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
  4. History of any one or more of the following cardiovascular conditions within the past 6 months:

    • Cardiac angioplasty or stenting, Myocardial infarction, Unstable angina, Coronary artery bypass graft surgery, Symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) classification.

  5. History or clinical evidence of CNS metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 1 week prior to first dose of study drug. Screening with CNS imaging (computerized tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases.
  6. Women who are pregnant or lactating. All females of childbearing potential must have negative serum or urine pregnancy tests within 7 days prior to study treatment.
  7. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥90mmHg]. [Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study.
  8. Presence of uncontrolled infection.
  9. Prolongation of heart rate-corrected QT interval (QTc) >480 msecs using Bazett's formula.
  10. Use of any of the medications on the prohibited medication list within 14 days of study treatment (with the exception of Amiodarone, which is prohibited from 6 months prior to screening through discontinuation from the study).
  11. A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  12. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
  13. Minor surgical procedures (with the exception of the placement of portacath or other central venous access) performed less than 7 days prior to beginning protocol treatment.
  14. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
  15. Patients who have previously received treatment with cetuximab.
  16. Patients with hemoptysis or tumor cavitation at baseline.
  17. Any prior history of hypertensive crisis or hypertensive encephalopathy.
  18. Pulmonary hemorrhage/bleeding event within 6 weeks prior to beginning study treatment.
  19. Any other non-pulmonary hemorrhage/bleeding event ≥grade 3 within 28 days of study treatment.
  20. Evidence or history of bleeding diathesis.
  21. Serious non-healing wound, ulcer, or bone fracture.
  22. Known or suspected allergy/hypersensitivity to any agent given in the course of this trial.
  23. Clinically significant gastrointestinal abnormalities.
  24. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
  25. Any condition that impairs the patient's ability to swallow whole pills.
  26. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels (Note: tumor abutting the vessels is acceptable, but contiguous tumor and vessels is not; CT with contrast is strongly recommended to evaluate such lesions).
  27. Cavitary lesions deemed to be at increased risk of bleeding.
  28. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib and/or erlotinib.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01027598

Locations
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
United States, Georgia
Suburban Hem Onc
Lawrenceville, Georgia, United States, 30045
United States, Ohio
Oncology Hematology Care
Cincinnati, Ohio, United States, 45242
United States, South Carolina
South Carolina Oncology Associates, PA
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States, 37404
Family Cancer Center
Collerville, Tennessee, United States, 38119
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
United States, Virginia
Virginia Cancer Institute
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
SCRI Development Innovations, LLC
GlaxoSmithKline
OSI Pharmaceuticals
Investigators
Study Chair: David R Spigel, M.D. SCRI Development Innovations, LLC
  More Information

No publications provided

Responsible Party: SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier: NCT01027598     History of Changes
Other Study ID Numbers: SCRI LUN 200
Study First Received: December 4, 2009
Last Updated: April 1, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by SCRI Development Innovations, LLC:
Lung Cancer
Previously Treated Advanced Non Small Cell Lung Cancer
Erlotinib
Pazopanib

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Erlotinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014